Longeveron Says Phase 2 ELPIS II Trial Surpassed The 50% Enrollment Threshold
Portfolio Pulse from Benzinga Newsdesk
Longeveron announced that its Phase 2 ELPIS II trial has surpassed the 50% enrollment threshold. The company has also activated an eighth clinical site to expedite the completion of the trial enrollment.
August 11, 2023 | 11:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Longeveron's Phase 2 ELPIS II trial has reached over 50% enrollment, and an additional clinical site has been activated to expedite the trial's completion.
The news is directly related to Longeveron and its ongoing Phase 2 ELPIS II trial. The surpassing of the 50% enrollment threshold and the activation of an additional clinical site to expedite the trial's completion are positive developments that could potentially boost investor confidence in the company and its stock. Therefore, the short-term impact on LGVN's stock price is likely to be positive.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100